J
Joachim G.J.V. Aerts
Researcher at Erasmus University Rotterdam
Publications - 366
Citations - 19989
Joachim G.J.V. Aerts is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 46, co-authored 319 publications receiving 14585 citations. Previous affiliations of Joachim G.J.V. Aerts include Cancer Institute & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Harry J. de Koning,Carlijn M. van der Aalst,Pim A. de Jong,Ernst Th. Scholten,Kristiaan Nackaerts,Marjolein A Heuvelmans,Jan-Willem J. Lammers,Carla Weenink,Uraujh Yousaf-Khan,Nanda Horeweg,Susan van 't Westeinde,Mathias Prokop,Willem P.Th.M. Mali,Firdaus A. A. Mohamed Hoesein,Peter M. A. van Ooijen,Joachim G.J.V. Aerts,Michael A. den Bakker,Erik Thunnissen,Johny Verschakelen,Rozemarijn Vliegenthart,Joan Walter,Kevin ten Haaf,Harry J.M. Groen,Matthijs Oudkerk +23 more
TL;DR: In this trial involving high-risk persons, lung-cancer mortality was significantly lower among those who underwent volume CT screening than among thoseWho underwent no screening.
Journal ArticleDOI
Gene expression-based classification of non-small cell lung carcinomas and survival prediction.
Jun Hou,Joachim G.J.V. Aerts,Bianca den Hamer,Wilfred F. J. van IJcken,Michael A. den Bakker,Peter Riegman,Cor van der Leest,Peter J. van der Spek,John A. Foekens,Henk C. Hoogsteden,Frank Grosveld,Sjaak Philipsen +11 more
TL;DR: The gene signatures identified are promising tools for histo-pathological classification of non-small cell lung cancer, and may improve the prediction of clinical outcome.
Journal ArticleDOI
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen,Heike Peulen,Ferry Lalezari,Vincent van der Noort,Jeltje F. de Vries,Joachim G.J.V. Aerts,Daphne W. Dumoulin,Idris Bahce,Anna-Larissa N. Niemeijer,Adrianus J. de Langen,Kim Monkhorst,Paul Baas +11 more
TL;DR: Stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC was well tolerated and a doubling of ORR was observed, but results did not meet the study's prespecified end point criteria for meaningful clinical benefit.
Journal ArticleDOI
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Martin Reck,Alexander Luft,Aleksandra Szczesna,Libor Havel,Sang We Kim,Wallace Akerley,Maria Catherine Pietanza,Yi-Long Wu,Christoph C. Zielinski,Michael Thomas,Enriqueta Felip,Kathryn A. Gold,Leora Horn,Joachim G.J.V. Aerts,Kazuhiko Nakagawa,Paul Lorigan,Anne Pieters,Teresa Sanchez,J. Fairchild,David R. Spigel +19 more
TL;DR: Addition of ipilimumab to chemotherapy did not prolong OS versus chemotherapy alone in patients with newly diagnosed extensive-stage disease SCLC, and no new or unexpected adverse events were observed.